Syndax Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced participation in several upcoming investor conferences. Key events include a fireside chat at the Citi 2023 Virtual Oncology Leadership Summit on February 21, a session at Cowen's 43rd Annual Healthcare Conference on March 6, a panel discussion on leukemia at the same conference on March 8, and another fireside chat at Barclays Global Healthcare Conference on March 15. Live webcasts of these discussions will be accessible via the Company’s investor website, where replays will also be available for a limited time. Syndax is focused on developing innovative cancer therapies, with key candidates currently in pivotal trials.

WALTHAM, Mass., Feb. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the upcoming investor conferences:

• A fireside chat at the Citi 2023 Virtual Oncology Leadership Summit at 2:00 p.m. ET on Tuesday, February 21, 2023
• A fireside chat at Cowen's 43^rd Annual Healthcare Conference at 9:10 a.m. ET on Monday, March 6, 2023 in Boston, MA
• A panel discussion on leukemia at Cowen's 43^rd Annual Healthcare Conference at 12:50 p.m. ET on Wednesday, March 8, 2023 in Boston, MA
• A fireside chat at the Barclays Global Healthcare Conference at 10:45 a.m. ET on Wednesday, March 15, 2023 in Miami, FL

A live webcast of the fireside chats can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the Menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-upcoming-investor-conferences-301745697.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

What are the key events Syndax Pharmaceuticals will participate in February and March 2023?

Syndax Pharmaceuticals will participate in the Citi 2023 Virtual Oncology Leadership Summit on February 21, Cowen's 43rd Annual Healthcare Conference on March 6 and 8, and the Barclays Global Healthcare Conference on March 15, 2023.

Where can I watch the Syndax Pharmaceuticals investor conference webcasts?

The investor conference webcasts for Syndax Pharmaceuticals can be accessed from the Investor section of their website, www.syndax.com.

What is the significance of revumenib and axatilimab in Syndax Pharmaceuticals' pipeline?

Revumenib and axatilimab are significant as they are currently in pivotal trials, targeting cancer therapies through innovative mechanisms.

On what date is the fireside chat at the Citi 2023 Virtual Oncology Leadership Summit scheduled?

The fireside chat at the Citi 2023 Virtual Oncology Leadership Summit is scheduled for February 21, 2023, at 2:00 p.m. ET.

What specific topics will be discussed during the Cowen's 43rd Annual Healthcare Conference?

During Cowen's 43rd Annual Healthcare Conference, Syndax will engage in a fireside chat and a panel discussion focused on leukemia.